New test detects toxic prions in blood
News Jun 14, 2014
The first cases of variant Creutzfeld Jakob Disease (vCJD) disease in humans occurred in the late 1990s and are thought to be the consequence of eating contaminated beef products. Since then, several cases of secondary infections caused by transfusions with blood from donors who subsequently developed vCJD have been reported, raising concerns about the safety of blood and blood products. A paper published in PLOS Pathogens on June 12 now describes an assay that can detect prions in blood samples from humans with vCJD and in animals at early stages of the (asymptomatic) incubation phase.
To develop the assay, Olivier Andréoletti, from the Ecole Nationale Vétérinaire de Toulouse, France, and colleagues first optimized a method called PMCA (for Protein Misfolding Cyclic Amplification). The method mimics in a test tube the process by which misfolded (toxic) prions propagate, and the researchers determined experimental conditions that enable efficient PMCA amplification of the vCJD agent in the blood.
Having defined such conditions, they show that the assay can detect vCJD in asymptomatic but infected animals in the early phase of the incubation period. They examined blood samples collected from infected sheep and macaques (vCJD-infected macaques are considered the best model of the human disease). In both models, the assay can accurately identify infected animals and detect the presence of vCJD prions in blood from macaques shortly after the initial infection (and several years before clinical disease onset).
Samples from human vCJD patients are rare, and none exist from individuals at preclinical stage of the disease. To test the assay in human blood, the researchers obtained samples from vCJD patients and non-infected controls and analyzed them blindly (i.e. the people who did the assays did not know which samples were which) in two different laboratories. The assay correctly and consistently identified three of the four vCJD affected patients, and yielded no false-positive result in any of the 141 healthy controls. The negative result in one of the vCJD samples raises the question of the potential absence of vCJD agent in the blood of certain patients.
The authors say their "results represent substantial progress towards an applicable vCJD blood detection assay. Such assay could be used to identify vCJD infected but asymptomatic individuals and/or for screening donated blood for the presence of the vCJD agent".
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Caroline Lacroux, Emmanuel Comoy, Mohammed Moudjou, Armand Perret-Liaudet, Séverine Lugan, Claire Litaise, Hugh Simmons, Christelle Jas-Duval, Isabelle Lantier, Vincent Béringue, Martin Groschup, Guillaume Fichet, Pierrette Costes, Nathalie Streichenberger, Frederic Lantier, Jean Philippe Deslys, Didier Vilette, Olivier Andréoletti. Preclinical Detection of Variant CJD and BSE Prions in Blood. PLoS Pathogens, Published June 12 2014. doi: 10.1371/journal.ppat.1004202
Expect a shot to hurt and it probably will, even if the needle poke isn’t really so painful. Brace for a second shot and you’ll likely flinch again, even though—second time around—you should know better. That’s the takeaway of a new brain imaging study which found that expectations about pain intensity can become self-fulfilling prophecies.
Intensive behavioral therapy (IBT), which provides diet and physical activity counseling, could help adults with obesity achieve meaningful weight loss in six to 12 months. The trial showed that patients who received IBT lost an average of 6.1 percent of their initial body weight at one year.READ MORE